Latest Forum Topics /
Clearbridge
Last:0.001
-0.001
|
 Post Reply
|
|
<No Title>
|
|||||
|
gregtan123
Supreme |
27-Nov-2020 09:44
|
||||
|
x 0
x 0 Alert Admin |
yes slowly others will appreciate this gem.
|
||||
| Useful To Me Not Useful To Me | |||||
|
Zerocool888
Master |
27-Nov-2020 09:35
|
||||
|
x 0
x 0 Alert Admin |
It' s nice to see this counter moving BUT most traders are shortists. Once it hits the roof, it' s back to square one. The good news only for short term happiness as I believe there are many longists still stuck at the high end. Trade with caution as 10 out of 10 times, this stock gave false hope. Not saying you can' t trade but your timing must be pretty spot on. I have plenty of lots in here as well and it' s still way below my average price. DYODD! |
||||
| Useful To Me Not Useful To Me | |||||
|
|
|||||
|
WBdisciple
Elite |
27-Nov-2020 09:31
|
||||
|
x 0
x 0 Alert Admin |
The Indonesia announcement is for their ANTIBODY test kit. The Spore (joy) is a ANTIGEN test kit...which is NEW in their product portfolio..Singapore is using ANTIGEN test kits now for its events testing...go GOOGLE it. With the HSA green light for the JOYSBIO ANTIGEN test kit (distributed by BIOLIDCICS), more demand from Southeast Asia govt agencies?? Clearbridge has a strong presence in Indonesia and Philippines. Pls do your own DD
|
||||
| Useful To Me Not Useful To Me | |||||
|
zulakuma86
Member |
27-Nov-2020 09:27
|
||||
|
x 0
x 0 Alert Admin |
So distribution rights for 2. Indonesia (biolidics) and Spore (joy)
|
||||
| Useful To Me Not Useful To Me | |||||
|
WBdisciple
Elite |
27-Nov-2020 09:21
|
||||
|
x 0
x 0 Alert Admin |
TOTAL OF TWO ANNOUNCEMENTS last night by Biolidics
https://www.biolidics.com/announcements
First one: Biolidics& rsquo COVID-19 Antibody Test Kits obtained the relevant authorisation from Kementerian Kesehatan Republik Indonesia, which is the Ministry of Health in Indonesia, for it to be distributed and used in Indonesia (the " Authorisation" ). The Authorisation remains valid until 25 November 2021 and the extension of its validity may be permissible should there be no undesirable events upon usage.
Second one: Biolidics entered into a distribution agreement (the " JOYSBIO Agreement" ) with JOYSBIO (Tianjin) Biotechnology Co, Ltd, a company incorporated in Tianjin, the People' s Republic of China (" JOYSBIO" ). JOYSBIO is the product owner of the medical device known as the " SARS-CoV-2 Antigen Rapid Test Kit (Colloidal Gold)"
Under the terms of the JOYSBIO Agreement, the Company has been appointed as the non-exclusive worldwide distributor of the JOYSBIO Antigen Rapid Test Kit for a duration of one year from the date of the JOYSBIO Agreement. In addition, under the terms of the JOYSBIO Agreement, among others, the Company shall automatically become the exclusive distributor of the JOYSBIO Antigen Rapid Test Kit in Singapore and the Philippines if the number of kits ordered by the Company reaches 100,000 units within 90 calendar days in Singapore and 1,000,000 units within 180 calendar days in the Philippines, from the date of the JOYSBIO Agreement (i.e. 26 November 2020), respectively.
The Company was appointed by JOYSBIO to prepare and submit applications to the Health Sciences Authority (" HSA" ) for provisional authorisation of the JOYSBIO Antigen Rapid Test Kit in Singapore (" Provisional Authorisation" ). The Company wishes to inform that the JOYSBIO Antigen Rapid Test Kit has, on 26 November 2020, received the Provisional Authorisation and the Provisional Authorisation shall remain valid until the HSA advises otherwise. The JOYSBIO Antigen Rapid Test Kit shall only be supplied to the healthcare institutions, private hospitals, medical clinics or clinical laboratories licensed under the Private Hospitals and Medical Clinics Act (PHMC Act) (Cap. 248) for use on their patients, for point-of-care testing and not for at-home testing.
|
||||
| Useful To Me Not Useful To Me | |||||
|
|
|||||
|
Thiamm
Veteran |
27-Nov-2020 08:31
|
||||
|
x 0
x 0 Alert Admin |
Only approval in Indonesia?
|
||||
| Useful To Me Not Useful To Me | |||||
|
WBdisciple
Elite |
27-Nov-2020 08:09
|
||||
|
x 0
x 0 Alert Admin |
Biolidics' Covid-19 test kits to be distributed and used in Indonesia THU, NOV 26, 2020 - 9:59 PM CATALIST-LISTED medtech firm Biolidics on Thursday said its Covid-19 antibody test kits had, on Wednesday, obtained authorisation from the Indonesian health authorities for distribution and use in Indonesia. The authorisation remains valid until Nov 25, 2021. The validity period may be extended " should there be no undesirable events upon usage" , Biolidics said. The company noted that results from the test kits are not to be used for confirmatory testing or as the sole basis for diagnosis. The results have to be interpreted together with clinical presentation and are to be confirmed with supplementary testing. It said shareholders and potential investors should note that policies relating to the diagnosis and detection of the Covid-19 virus and antibodies in various jurisdictions may change in response to developments in the Covid-19 situation, which is evolving rapidly. |
||||
| Useful To Me Not Useful To Me | |||||
|
hotelgrand
Master |
26-Nov-2020 14:58
|
||||
|
x 0
x 0 Alert Admin |
So many convertible loans to shares..good for company as co no need to repay debt but large overhang of supply capped share price from moving up | ||||
| Useful To Me Not Useful To Me | |||||
|
|
|||||
|
Nick90
Member |
26-Nov-2020 14:07
Yells: "Always all-in." |
||||
|
x 0
x 0 Alert Admin |
What is the indication of those robot buying with 100units 100units 100units ...... | ||||
| Useful To Me Not Useful To Me | |||||
|
Zerocool888
Master |
26-Nov-2020 11:44
|
||||
|
x 0
x 0 Alert Admin |
It' s moving for sure. Need to wait very very long for this to reach it' s potential. |
||||
| Useful To Me Not Useful To Me | |||||
|
wehuattogether88
Supreme |
26-Nov-2020 11:23
|
||||
|
x 0
x 0 Alert Admin |
Clearbridge is clearing and moving its way slowly. | ||||
| Useful To Me Not Useful To Me | |||||
|
zulakuma86
Member |
26-Nov-2020 07:15
|
||||
|
x 0
x 0 Alert Admin |
thank you for sharing. In line with CB' s precision medicine and personalised care. 
|
||||
| Useful To Me Not Useful To Me | |||||
|
|
|||||
|
WBdisciple
Elite |
26-Nov-2020 07:07
|
||||
|
x 0
x 0 Alert Admin |
Precision medicine key to preventing disease: Panel Straits Times senior health correspondent Salma Khalik with (from left) Health Promotion Board chief executive Zee Yoong Kang, Health Ministry chief health scientist Tan Chorh Chuan and Prudential chief executive Dennis Tan at the webinar yesterday. An individual' s genes can determine the amount of risk he has of developing life-threatening conditions such as heart disease and, in turn, allow for early intervention. Achieving such outcomes is central to the precision medicine programme here, said Professor Tan Chorh Chuan, the chief health scientist of the Ministry of Health and executive director of its Office for Healthcare Transformation. Prof Tan told a webinar yesterday that the research programme looks at the genome sequences of participants and how these may relate to health. For example, the presence of certain gene mutations could increase the risk of specific diseases. This can be particularly useful for some complaints like premature heart disease, added Prof Tan, who was joined on the webinar panel by Prudential chief executive Dennis Tan and Health Promotion Board (HPB) CEO Zee Yoong Kang. The event, which covered a broad range of health topics from diabetes and vaccines to strategies on how to stay healthy, is part of The Straits Times Reset 2021 webinar series. It was sponsored by Prudential and moderated by ST senior health correspondent Salma Khalik. Prof Tan told the webinar that a condition known as familial hypercholesterolaemia is caused by gene mutations that result in high cholesterol levels at a much younger age. The affected person may have up to 20 times higher risk of heart disease and at an earlier age. " And then if we identify somebody, we can also test the family. So these preventative strategies will be part of precision health," he added. The HPB is working to make use of clinical, behavioural, digital and genetic data - with patient consent - to identify those at higher risk to allow for early intervention. Prudential' s Mr Tan said Singaporeans need not worry about being part of the programme or be concerned about finding out their genome sequences. Having " bad" genes will not make it harder for them to secure insurance policies, he noted. Privacy is really important, Mr Tan said, adding that " we (Prudential) are very, very careful about such things" . He said individuals ultimately have to take charge of their own health and want to find out more. " Preventative healthcare is all about them being in the driver' s seat, and going through the whole process of early detection, health screening and all. " So I think as insurers, we will definitely support them." Ms Khalik said that if a person learns that he is at high risk of a certain disease, it will give him the time and opportunity to act before the ailment takes hold. |
||||
| Useful To Me Not Useful To Me | |||||
|
Zerocool888
Master |
25-Nov-2020 12:01
|
||||
|
x 0
x 0 Alert Admin |
This counter need to wait for now. Until post COVID-19 arrives, we won' t be able to witness their true potential. Many investors are stuck with this counter. I am sure some have let go at a loss as they don' t see the actual potential yet. Most was made to believe that they were going to distrubute the test kits (not their core business) but was poured with icy cold water by a certain individual whom most of us know that was...... Those who are still holding on to this counter, if you can still hold......you will see the light at the end of the tunnel but it' s a very long tunnel. While other med stock core business is about producing gloves or test kits (which the demand will eventually fade off), those who vested this counter should know their core business lies in their main foundation which are healthcare such as clinics and hospitals. In Asia, healthcare are still very much in demand as people are living longer and there more elderly folks which needs these service. It' s good to read again the below article and can understand better on CB approach. No companies on this planet plans to do business at a loss. So, each company will have their own set dateline. |
||||
| Useful To Me Not Useful To Me | |||||
|
WBdisciple
Elite |
24-Nov-2020 10:10
|
||||
|
x 0
x 0 Alert Admin |
Article below is published on Business Times in APRIL 2020. A bit dated but it shows the vision of Clearbridge Health (led by Jeremy Yee) is taking shape: Clearbridge' s ' build, borrow, buy' approach MON, APR 27, 2020 - 5:50 AM Mr Yee says: " Healthcare is pretty much an under-served market here, given Asean' s population base of more than 655 million. With a feasible business model, you can easily capture a multitude of opportunities." NURTURING talent and unlocking human potential are lifelong passions for healthcare entrepreneur Jeremy Yee. " What truly inspires me is the process of identifying and grooming the next generation of leaders and entrepreneurs, who can grow faster than the organisation," said the chief executive of SGX-listed precision medicine services firm Clearbridge Health. " The joy comes from being a variable in the equation where people develop to their fullest potential. After all, products do not move by themselves - it is the human capital that makes things happen." That' s why Mr Yee feels his journey in healthcare - spanning nearly two decades - has reaped multiple rewards despite myriad challenges along the way. " The key is having a learning mindset. In mentoring and coaching others, I find myself developing and growing as well - that' s the most satisfying part of the process," he added. A holder of Master' s degrees in Arts, Commerce and Business Administration from universities in the US, Australia and Singapore, he was named executive director and chief executive of Clearbridge Health in May 2017. Prior to this appointment, from 2011 to 2016, he helmed SGX-listed cord blood banking services company Cordlife Group. Between 2002 and 2011, he held chief financial officer and chief operating officer roles with ASX-listed Cordlife. The early part of his career was spent in the banking and finance industry. Mr Yee' s decision to focus on healthcare stems largely from a desire to cater to what he sees as a pressing and growing need in the region. " Healthcare is pretty much an under-served market here, given Asean' s population base of more than 655 million. With a feasible business model, you can easily capture a multitude of opportunities." In particular, precision medicine - which tailors drug treatments to individual patients based on their genes, lifestyle, and environment - has an increasing relevance today. " The best healthcare strategy is a patient-centric, customised approach, rather than a one-size-fits-all method of disease treatment and prevention," he said. " If we want to improve diagnoses and treatments for patients with critical or chronic illnesses like cancer and diabetes, it' s important to understand their underlying conditions, so as to provide targeted therapy." According to projections by Research and Markets, the global precision medicine market could be valued at US$216.8 billion by 2028, reflecting a compound annual growth rate (CAGR) of 10.6 per cent. The Asia-Pacific market - the world' s fastest-growing - was valued at US$11 billion in 2018, and is anticipated to hit US$20.9 billion by 2023, expanding at a CAGR of 16.6 per cent, data from Ken Research showed. Key drivers include a rapidly ageing population, longer life spans and technological advances. This is where Clearbridge Health, with its precision medicine tools and technologies, can play an important and expanding role. " First, in terms of scope, we can provide relevant products and services using a pricing model that is affordable," Mr Yee said. " Second, in terms of scale, we can offer these services to doctors and patients, both in Singapore and across markets in South-east Asia." Established in 2010 in Singapore and known then as Clearbridge Accelerator, the company invested in medical technology and incubated global deep-tech healthcare firms. In 2017, the business expanded to include medical clinics and strategic stakes in precision medical technology companies. Listing on SGX' s Catalist board in December 2017, Clearbridge Health now has a growing network of owned and operated primary healthcare touchpoints as well as healthcare systems across Asia. The group also has stakes in three medical technology firms - 23.1 per cent-owned associate Biolidics, which listed on Catalist in December 2018 Clearbridge Biophotonics and the Singapore Institute of Advanced Medicine Holdings. Last month, Biolidics announced the launch of a rapid test kit for Covid-19 that uses serum, plasma or whole blood samples to test for the novel coronavirus. The kit has obtained provisional authorisation from Singapore' s Health Sciences Authority, relevant authorisation from the Food and Drug Administration of the Philippines, as well as the Conformitè Europë enne (CE) Marking for use in the European Union. " Our vision is to bring high-quality healthcare and solutions to the masses through a distribution model that makes it readily available and affordable - such as a Public-Private Partnership model, in countries with national health insurance systems like the Philippines and Indonesia," Mr Yee said. " As a private player adding expertise and working with public hospitals on the ground, we want to change the way local patients receive and experience healthcare." A case in point is Indonesia, where Clearbridge currently manages a total of 49 hospital joint operation contracts, serving close to four million patients a year, primarily in the area of renal care and pathology. Thanks to its Indonesian operations, the group' s healthcare systems business unit was the major revenue contributor in 2019, with sales surging more than four-fold to S$15.6 million. But even as demand for quality healthcare in the region continues to accelerate, challenges abound. The most obvious are operational issues - " especially when the healthcare sector in Asia is fragmented, with policies and regulations diverging across countries" , he said. To drive expansion, Clearbridge has adopted a three-pronged approach - building, borrowing and buying. The group aims to enlarge its network in existing countries, and expand into new, populous markets via the public-private-partnership model where relevant. " We' re not an earnings aggregator - we don' t buy clinics to boost our profits," Mr Yee added. " Instead, we want to accumulate skills and expertise to expand, as well as improve the quality of treatments that patients receive, especially beyond Singapore, as South-east Asia is our hinterland." The group is also deliberately prudent in its acquisitions. " We require every entity we buy to be Ebitda- (earnings before interest, tax, depreciation and amortisation) positive and contribute immediately to our financial performance." Other hurdles include market volatility and valuation. " Clearbridge is moving towards profitability, but market volatility is such that it doesn' t give entrepreneurs an opportunity to exploit capital markets for growth," Mr Yee said. Clearbridge' s market capitalisation - currently about S$117 million - has shrunk slightly from its initial public offer (IPO) market cap of S$135 million. For the year ended Dec 31, 2019, the group reported a revenue of S$21.5 million, up nearly four-fold. " It' s been a challenge to successfully convey our entrepreneurial vision to investors, and the market has limited tools with which to evaluate high-growth companies like us," Mr Yee said. As a result, Clearbridge Health remains largely unrecognised by the market, with Ebitda and revenues moving in opposite directions to its share price, he added. " We own proprietary technologies, and an associate like Biolidics that' s supporting us in novel diagnostic capabilities," he added. " We have an asset-light business model, and no direct competitor in Singapore - our closest peers are private hospital groups with more assets in real estate than medical products and services." Maintaining a balance between growth and cashflows also keeps Mr Yee up late into the night. Sometimes, the epiphany comes during one of his daily 10-km runs. But more often than not, a decision is reached after brainstorming with the rest of his team. And for the 50-year-old father of two girls and a boy aged 14 to 20, leading by example is paramount. Cultivating integrity, a razor-sharp focus and resilience are also at the top of his list. " The key defining characteristic of an entrepreneur centres on how he or she deals with problems. Entrepreneurs never give up - if they feel deep in their gut that this is the right thing to do, they will die trying." |
||||
| Useful To Me Not Useful To Me | |||||
|
Zerocool888
Master |
24-Nov-2020 09:26
|
||||
|
x 0
x 0 Alert Admin |
Read this article few days ago. As reported, this is a long investment and will only see the fruit bearing when post COVID comes into play. Their current target price is still low at 186 when i think most investors bought at above 220-240. It will be a very long wait indeed. |
||||
| Useful To Me Not Useful To Me | |||||
|
Joelton
Supreme |
24-Nov-2020 09:18
|
||||
|
x 0
x 0 Alert Admin |
Clearbridge Health: Here&rsquo s a stock that stands to benefit from Southeast Asia&rsquo s rapidly growing healthcare market
● Clearbridge Health Limited (SGX:1H3) is a fast-growing healthcare company focused on the delivery of precision medicine tools in Asia.
● Southeast Asia&rsquo s large underserved populations, particularly in Indonesia, Philippines and Vietnam will bring about a strong demand for healthcare services, presenting many opportunities for healthcare companies in time to come.
● Governments have also recognised the need for healthcare reforms and are partnering with private players for the provision of healthcare services.
● Clearbridge has employed a public-private partnership (PPP) model to offer much needed healthcare services and is gaining a foothold within the Southeast Asian region.
● We maintain our target price of SGD 0.185 on Clearbridge Health. Based on its closing price of SGD 0.135 on 20 November 2020, it translates to an upside potential of 37%.
|
||||
| Useful To Me Not Useful To Me | |||||
|
WBdisciple
Elite |
23-Nov-2020 16:50
|
||||
|
x 0
x 0 Alert Admin |
Here&rsquo s a stock that stands to benefit from Southeast Asia&rsquo s rapidly growing healthcare market
Here is iFast&rsquo s latest research report on Clearbridge Health: https://secure.fundsupermart.com/fsm/article/view/rcms216820/here-s-a-stock-that-stands-to-benefit-from-southeast-asia-s-rapidly-growing-healthcare-market
● Clearbridge Health Limited (SGX:1H3) is a fast-growing healthcare company focused on the delivery of precision medicine tools in Asia.
● Southeast Asia&rsquo s large underserved populations, particularly in Indonesia, Philippines and Vietnam will bring about a strong demand for healthcare services, presenting many opportunities for healthcare companies in time to come.
● Governments have also recognised the need for healthcare reforms and are partnering with private players for the provision of healthcare services.
● Clearbridge has employed a public-private partnership (PPP) model to offer much needed healthcare services and is gaining a foothold within the Southeast Asian region.
● We maintain our target price of SGD 0.185 on Clearbridge Health. Based on its closing price of SGD 0.135 on 20 November 2020, it translates to an upside potential of 37%.
|
||||
| Useful To Me Not Useful To Me | |||||
|
Zerocool888
Master |
19-Nov-2020 13:37
|
||||
|
x 0
x 0 Alert Admin |
Patience need to have for sure. Was wondering why the stock was sleeping earlier. Finally moving liao.........lol........
|
||||
| Useful To Me Not Useful To Me | |||||
|
WBdisciple
Elite |
19-Nov-2020 10:54
|
||||
|
x 0
x 0 Alert Admin |
We have a steady hand with Jeremy Yee helming the Company...have a bit more patience. | ||||
| Useful To Me Not Useful To Me | |||||